CLAIM CARD
Methodological challenges complicate the interpretation of Metformin Effects for geroprotective purposes. Heterogeneity across the evidence base is substantial: the present corpus surfaces cross-study disagreements across outcome classes, with effect directions varying from positive to null to negative even within cardiometabolic outcomes. Trial durations in the diabetes literature—commonly 12 to 24 weeks—are considerably shorter than what aging biology endpoints would require, and concurrent interventions such as exercise training may interact with metformin in ways that attenuate adaptive responses (Malin 2026; Malin 2026b). Dose standardization is further complicated by formulation differences, as extended-release and immediate-release metformin yield divergent gastrointestinal tolerability profiles (Alshadfan 2026). Methodological challenges complicate the interpretation of Metformin Effects for geroprotective purposes. Source documents were screened for quantitative outcome statements, and 3049 extracted quantitative findings were retained for synthesis after role, unit, and citation checks. Corpus construction used the topic query terms with aging, longevity, healthspan, frailty, cardiometabolic, immune, safety, and function terms across bibliographic, trial, and project-curated source indexes when available. The output is therefore framed as a structured evidence synthesis rather than a claim of exhaustive systematic-review coverage.
Evidence grade: exploratory
Contradiction status: none
Publication: 5f566366-fb20-4402-ba24-c1117573f97f
Provenance: Derivation Web chain
Citation Support
source_1Zaveri 2026source_2Wu 2026source_3Hong 2026source_4Lee 2026source_5Seo 2026